I didn't say it couldn't. Dolcevita seems to be pinning a lot of hope on TAVR. I am just saying there are other things going for the company that should see (or should have seen) it succeed and focusing on future tech that no one knows much about is, to me, a bit desperate. Before this the vax was going to solve all AHZ problems. Things fail all the time. AHZ has a product that apparently works but is still failing which is the real concern.
I'm also saying that given how low value AHZ is at the moment, if you were a multi billion dollar company looking to get into TAVR, why not just bail AHZ out and buy up the register? Like Starbright appears to be doing?
Chochlear has a market cap of $9.9 billion. AHZ is $47.5 million.
Ann: Appendix 4C - quarterly, page-140
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.10 |
Change
-0.810(8.17%) |
Mkt cap ! $196.8M | |||
| Open | High | Low | Value | Volume |
| $9.50 | $9.77 | $9.01 | $212.2K | 22.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 298 | $9.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.85 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |